Two Highly Engaged Volunteer Leaders Elected to Head Breakthrough T1D’s International Board of Directors
Karen Shishino Jordan, a long-time volunteer leader in the greater California Bay area, will serve as Breakthrough T1D (formerly JDRF) International Board of Directors (IBOD) Chair, succeeding current Chair Lisa Fishbone Wallack. Carlton McMillan, also a dedicated volunteer leader in the greater California Bay area, will serve as Vice Chair, succeeding current Vice Chair Matt Varey. Karen’s and Carlton’s terms as Chair and Vice Chair, respectively, begin Wednesday, July 1, 2026. Breakthrough […]
Deceased Donor Islet Cell Transplantation 101
Our Statement on Deceased Donor Islet Cell Availability & The ISLET Act Curing type 1 diabetes (T1D) is Breakthrough T1D’s number one priority. As the leading global T1D research and advocacy organization, we are currently funding over $450 million in cures research in 23 countries. Everything we do is focused on making cures happen for the T1D […]
Q&A with Patti Columbe: A glimpse into her journey with Vertex’s manufactured islets
Breakthrough T1D had the pleasure of speaking with Patti Columbe, a participant in Vertex’s pivotal trial for the manufactured islet therapy zimislecel (formerly VX-880). Patti has been living with type 1 diabetes (T1D) for nearly 39 years. This is one of the most exciting T1D trials in terms of getting us closer to cures for […]
A new Breakthrough T1D publication is paving the way for beta cell replacement therapies
Breakthrough T1D’s newest publication outlines a roadmap for beta cell replacement therapies for type 1 diabetes.
New publication alert: Engineered islets are making insulin and avoiding immune detection in first person treated
Hypoimmune (HIP) islets are making insulin, without immunosuppressants, in the first person treated with type 1 diabetes.
Accelerating cures: Four new grants from the Breakthrough T1D x Stem Cell Network Partnership
Breakthrough T1D, Breakthrough T1D Canada, and the Stem Cell Network (SCN) have partnered to support cell therapy research in Canada.
Making cures a reality: Clinical adoption of cell therapies
The Medical Affairs team is working to ensure the clinical adoption of forthcoming manufactured cell therapies.
Breakthrough T1D helps organize an event at the European Parliament about unmet needs for T1D and accelerating cures
This meeting focused on the role of the EU in addressing the needs of the T1D community and accelerating T1D breakthroughs.
The essential role of Advocacy in advancing T1D cell therapies
Breakthrough T1D's Advocacy efforts contribute to clear and efficient policies and secure government funding for manufactured cell therapies.
Medical Affairs team kicks off international islet cell therapy workshops at Breakthrough T1D HQ
Breakthrough T1D's Medical Affairs team hosted experts in islet transplantation to discuss a clinical roadmap for manufactured cell therapies.
